Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof-of-concept trial of intranasal epinephrine (G2B011)

Trial Profile

Proof-of-concept trial of intranasal epinephrine (G2B011)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epinephrine (Primary)
  • Indications Anaphylaxis
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors G2B Pharma; Shin Nippon Biomedical Laboratories
  • Most Recent Events

    • 13 Oct 2014 New trial record
    • 13 Aug 2014 Results published in G2B Pharma media release.
    • 13 Aug 2014 This proof-of-concept trial was successfully completed in 2013, according to a G2B Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top